After decades of pro-abortion administrations gradually loosening every last safeguard, the Trump administration’s FDA will conduct “its own review of the evidence, including real-world outcomes and evidence, relating to the safety and efficacy of the drug,” the Sept. 19 letter stated. The Trump administration has largely tried “to get out of the culture war side of the abortion issue,” as Vice President JD Vance put it, arguing that “abortion policy should be made by the states” after the Dobbs decision. Pro-life leaders have consistently lobbied on this point; as recently as late July, dozens of Baptist leaders urged “immediate action to stop the mail-order distribution of the abortion drug mifepristone, which now accounts for more than 60% of all U.S. abortions” and “has caused serious adverse events in nearly 11% of users and poses grave risks to women—especially when dispensed without in-person screening or ultrasound evaluation.” The recent letter by 22 state attorneys general continues the trend as evidence of the widespread momentum for restoring common sense safety precautions on mifepristone.
Author: Joshua Arnold
Published at: 2025-09-28 20:00:00
Still want to read the full version? Full article
